Clean Science and Technology Navigates Market Headwinds with Strategic Growth Initiatives

Clean Science and Technology Limited, a prominent player in the specialty chemicals sector, recently announced its financial results for the third quarter and nine months ended December 31, 2025 (Q3 FY26). The company's performance reflects a challenging global business environment marked by muted customer offtake, pricing pressures, and tariff-related uncertainties. Despite these headwinds, Clean Science demonstrated strategic resilience, particularly through its HALS business and backward integration efforts.

For Q3 FY26, the company reported a consolidated total revenue of INR 219 crore, a moderation from previous quarters, declining 11% quarter-on-quarter and 9% year-on-year. Consolidated EBITDA stood at INR 72 crore, with EBITDA margins at 33.4%. Profit after tax (PAT) was INR 46 crore, translating to a PAT margin of 21.2%. The nine-month consolidated revenue for FY26 reached INR 707 crore, showing a modest 1% increase year-on-year, primarily driven by new product launches.

Financial Snapshot: Q3 FY26 Consolidated Performance

Segmental and Geographic Performance

The Performance Chemical segment remained the largest contributor to consolidated revenue, accounting for 76% in 9M FY26, followed by Pharma & Agro Intermediates at 17% and FMCG Chemicals at 7%. The Performance segment was most impacted by volume-led declines in products like MEHQ and BHA, although the company noted no domestic competition in these specific products. The FMCG segment experienced a volume decline in its 4-MAP product, partly due to the loss of a key customer in China and indirect tariffs affecting end customers in the US.

Geographically, India contributed 38% to the 9M FY26 consolidated revenue, with China at 20%, Americas at 19%, Europe at 14%, and the Rest of the World (ROW) at 9%. The international markets, particularly Europe and the US, saw a decent decline in sales, attributed to tariffs and lower global acrylic acid prices.

Strategic Initiatives and Future Outlook

Despite the challenging environment, Clean Science made notable progress on its strategic initiatives. The HALS business delivered robust year-on-year growth of 55% in Q3 FY26, driven by a favorable product mix and higher contribution from cost-efficient higher derivatized HALS polymers. Significantly, the subsidiary Clean Fino Chem Limited achieved EBITDA breakeven, underscoring the success of its HALS expansion.

A key development was the commercialization of the new hydroquinone and catechol plant in December 2025. This backward integration is expected to provide immediate margin benefits by moderating raw material costs for downstream products such as TBHQ and Veratrole. Customer trials for these products are ongoing, with sales anticipated to commence from February 2026 and gradually increase through March, contributing decent numbers in FY27.

The company's greenfield capex for Performance Chemical 2 is on track, though commissioning has been delayed by approximately a quarter, now expected by May-June 2026. Revenues from this facility are projected to begin in Q4 FY27 after customer approvals and initial operational stabilization. The management highlighted that the total capital infusion in the subsidiary during the last nine months was INR 150 crore, bringing the total investment to around INR 700 crore.

Clean Science continues its steadfast focus on research and development, with 4 independent R&D labs and over 90 scientists. This commitment to innovation drives the development of unique, sustainable, and cost-effective catalytic manufacturing processes, positioning the company for long-term growth in high-value specialty chemicals. The company also maintains a strong financial position, being debt-free and holding INR 450 crore in cash, enabling disciplined capital allocation for growth and shareholder returns, including an interim dividend of INR 2 per share approved for Q3 FY26.

Management Commentary and Investor Confidence

Management acknowledged the challenging conditions, describing Q2 and Q3 FY26 as not their